Radiation boost may help CAR-T cells wipe out stubborn lymphoma
NCT ID NCT05514327
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving a special type of radiotherapy (ultra-fraction) before CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 20 adults who have failed at least two prior treatments will receive the radiotherapy followed by CAR-T cells. The main goal is to see how many patients respond at 3 months, with longer-term follow-up for progression and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ultra-fraction radiotherapy and CD19 CAR-T cell therapy
What this could lead to
If it works, this could improve how well CAR-T therapy controls lymphoma in patients who have run out of other options.
What could go wrong
This is a very small, early study with only 20 participants, so results may not apply widely. The combination could also cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Email: •••••@•••••